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MethamphetamineWe recently published data that showed low dose of methamphetamine is neuroprotective when delivered 3 h
after a severe traumatic brain injury (TBI). In the current study, we further characterized the neuroprotective
potential of methamphetamine by determining the lowest effective dose, maximum therapeutic window, phar-
macokinetic proﬁle and gene expression changes associatedwith treatment. Graded doses ofmethamphetamine
were administered to rats beginning 8 h after severe TBI. We assessed neuroprotection based on neurological
severity scores, foot fault assessments, cognitive performance in the Morris water maze, and histopathology.
We deﬁned 0.250 mg/kg/h as the lowest effective dose and treatment at 12 h as the therapeuticwindow following
severe TBI. We examined gene expression changes following TBI and methamphetamine treatment to further
deﬁne the potential molecular mechanisms of neuroprotection and determined that methamphetamine signiﬁ-
cantly reduced the expression of key pro-inﬂammatory signals. Pharmacokinetic analysis revealed that a 24-hour
intravenous infusion of methamphetamine at a dose of 0.500 mg/kg/h produced a plasma Cmax value of
25.9 ng/ml and a total exposure of 544 ng/ml over a 32 hour time frame. This represents almost half the
24-hour total exposure predicted for a daily oral dose of 25 mg in a 70 kg adult human. Thus, we have demon-
strated that methamphetamine is neuroprotective when delivered up to 12 h after injury at doses that are com-
patible with current FDA approved levels.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Currently there are no approved therapeutic interventions available
to prevent cognitive and behavioral deﬁcits following traumatic brain
injury (TBI) (Beauchamp et al., 2008). The development of viable treat-
ments has been hindered by the fact that TBI represents a heteroge-
neous injury that activates multiple neuropathological pathways
(Beauchamp et al., 2008; Dolan et al., 2012; Elder et al., 2010; Martin
et al., 2008; Okie, 2005). During the primary injury phase, there is a
rapid, uncontrolled release of glutamate that leads to calciumdysregula-
tion, the production of reactive oxygen species (ROS), reactive nitrogen
species (RNS), lipid peroxidation products, the release of prostaglandins,Biomedical and Pharmaceutical
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c.Open access under CC BY-NC-ND liceand the generation of nitric oxide (NO) (Pitkanen et al., 2009; Schober
et al., 2012; Shultz et al., 2012; Stoica and Faden, 2010; Zhang et al.,
2005). Consequently, these molecules induce microglial activation
(Blaylock and Maroon, 2011; Block et al., 2007; Brown and Neher,
2010). Microglia are key mediators of both inﬂammatory responses and
glutamate release (Brown and Neher, 2010). When activated in the pres-
ence of excessive glutamate,microglia exhibit a neuro-destructive pheno-
type and secrete pro-inﬂammatory cytokines such as interleukin-6 (IL-6),
tumor necrosis factor alpha (TNF-alpha), and interleukin-1 (IL-1) (Block
et al., 2007; Brown andNeher, 2010; Stoica and Faden, 2010). The release
of these cytokines induces a cascade of neuro-inﬂammation that perpet-
uates glutamate excitotoxicity and microglial activation eventually lead-
ing to neuronal loss and permanent neurological dysfunction (Blaylock
and Maroon, 2011; Stoica and Faden, 2010).
Thus, survivors of severe TBI are likely to experience a degree of
lasting neurological impairment, a permanent reduction in cognitive
abilities, and psychological disturbances (Daneshvar et al., 2011;
Dempsey et al., 2009). In the United States, 1.7million individuals suffer
from a TBI every year (Prevention C.f.D.C.a, 2006; Reeves and Panguluri,
2011; Saulle and Greenwald, 2012). Clearly, there is a crucial unmet
need to develop novel, effective therapies that can be administerednse.
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recently published data demonstrating that administration of low dose
methamphetamine following severe TBI resulted in improved function-
al and cognitive outcomes (Rau et al., 2012). In this previous study, we
administered methamphetamine beginning 3 h after a severe TBI.
While promising, a 3-hour delay to treatment does not represent a clin-
ically relevant time frame. Therefore, in the present studywe examined
the therapeutic potential of methamphetamine at later time points. In
addition, we more thoroughly characterized the pharmacology of
methamphetamine by performing a dose response study and pharma-
cokinetic analysis. Finally, we examined critical gene expression chang-
es in an effort to understand the potential molecular mechanisms of
methamphetamine-mediated neuroprotection.
Methods
The Institutional Animal Care and Use Committee at The University
of Montana approved all procedures in these studies. Adult, male,
Wistar rats (350–500 g) were obtained from Charles River Laboratories
(Wilmington, MA) and housed in ﬁltered isolator boxes with a 12-hour
light/dark schedule and ad libitum access to food and water. The lateral
ﬂuid percussion injury procedure was performed aswe have previously
published (Rau et al., 2012). Brieﬂy, animals were deeply anesthetized
using 2–4% isoﬂourane. A 5 mm trephination was made over the right
hemisphere equidistant from the lambda and the bregma as we previ-
ously described (Rau et al., 2012). Animals were given a 20 ms ﬂuid
pulse to the dura at 1.9–2.3 ATM of pressure. Approximately 25% mor-
tality was observed with these pressures. All animals became apneic
after injury and were manually ventilated with supplemented O2 until
normal breathing resumed. At 7.5 or 11.5 h post-injury, an Alzet osmotic
pump (Alzet corp; 2001D; 8.4 μL per hour) containing a methamphet-
amine solution designed to deliver 0.500, 0.250, or 0.250 mg/kg/h for
24 h was surgically implanted into the inguinal crease and connected to
the femoral vein through a catheter as we previously described (Rau
et al., 2012). The catheter (Scientiﬁc Commodities; Lake Havasu, AZ)
from the pump was pre-loaded with a solution of 50% dextrose/50%
heparin to prevent clotting. The length of the catheter and inner diameter
were calculated to ensure methamphetamine delivery to the end of the
catheter 30 min after insertion into the animal. At 8 or 12 h post injury,
the animals were lightly anesthetized and a bolus dose of saline ormeth-
amphetamine was injected into the tail vein to coincide with the be-
ginning of the pump delivery into the femoral vein. Bolus dosing for
the 0.500 mg/kg/h dose was 0.425 mg/kg, 0.212 mg/kg for the
0.250 mg/kg/h dose, and 0.106 mg/kg for the 0.125 mg/kg/h dose.
Saline and sham treated animals underwent the same procedure
receiving pre-warmed saline. 72 h after injury the animals were re-
anesthetized and the Alzet pumps were removed (Rau et al., 2012).
Neurological severity scoring
Neurological severity scoring (NSS) was performed as previously
described (Rau et al., 2011, 2012). NSS and foot fault assessments
were conducted on days 1, 7, 14, 21, 30, and day 40. Animals were
scored from 0–16 with 16 indicating maximal impairment. Scoring
criteria for a severe TBI was 16-10, Animals scoring 9 or less on day 1
were excluded as a moderate/mild injury.
Foot faults assessments
Foot fault assessments were conducted as previously described
(Rau et al., 2012). Brieﬂy, rats were set on an elevated grid. With
each weight-bearing step, the paw may fall or slip off the wire grid.
Each time the left forelimb (affected by damage to the right hemisphere)
missed a placement on the wire rack it was recorded as a foot fault. The
total number of steps (weight bearing movement of the right forelimb)
that the rat used to cross the grid was counted, and the total number of
foot faults for each forelimb was recorded.Assessment of cognitive function
The Morris water maze (MWM) was used to assess the impact of
methamphetamine on cognitive function (learning and memory) fol-
lowing TBI. The assessment procedure was performed as previously
published (Rau et al., 2012). Pre-acclimation began on day 39 post-
injury. The training phase began on day 40 post-injury, and the probe
trial was conducted on day 45 post-injury. The water temperature was
maintained at a constant 19 °Celsius with the clear plexiglas platform
2 cm below the water level. All data was recorded and analyzed using
Anymaze software connected to a Logitech camera. All data sets were
analyzed by a blinded researcher. There were no signiﬁcant differences
in swim speeds between any of the animals.
Immunohistochemistry
Forty-six days after TBI, rats were deeply anesthetized and perfused
with 4% paraformaldehyde (PFA) ﬁxative. Brains were post-ﬁxed for
24 h at 4 °C in 4% PFA and divided into 2 mm coronal sections using a
rat brain matrix. Slices were processed, parafﬁn embedded and sec-
tioned at 7 μm. A 1 in 10 series from each rat was surveyed to identify
location relative to Bregma. Sections were mounted at Bregma −3.3,
deparafﬁnized and rehydrated. Antigen retrieval by treatment in 0.1 M
citric acid pH 6 was performed, and sections were stained for a pan-
axonal neuroﬁlament marker (NF312 Covance, Princeton NJ) at a dilu-
tion of 1:1500 overnight at 4 °C in a humid chamber. Slideswerewashed
with PBS 3 × 5 min and incubatedwith AlexaFluor 488 Goat anti Mouse
IgG (Invitrogen, Life Technologies, Grand Island, NY) at a dilution of
1:300 for 1 h at room temperature in the dark. After rinsing in PBS
3 × 5 min nuclei were counterstained with DAPI (Invitrogen) dilut-
ed to 1 μg/ml in PBS for 5 min. Sections were rinsed in PBS, rinsed
brieﬂy in ddH2O and coverslipped using FluorSave mounting media
(Calbiochem, Darmstadt, Germany). Adjacent sections at Bregma−3.3
were deparafﬁnized, rehydrated, and permeabilized in 0.1% TritonX100
in PBS for 20 min. Following a PBS rinse slides were stained for 488
NeuroTrace (Molecular Probes, Life Technologies, Grand Island, NY) at a
dilution of 1:400 overnight at 4 °C to label neurons. After NeuroTrace
labeling, sections were rinsed in PBS 3 × 5 min and counterstained
with DAPI as above. All sections were imaged on an Olympus Fluoview
FV1000 confocal microscope (Olympus, USA), capturing the single
brightest plane of ﬂuorescence. For NF312 stained slides, images were
captured at 40× (1.5 zoom) for the CA3 region of the hippocampus. Inte-
grated Optical Density (IOD, a measure of area multiplied by the average
density of staining) and axon length (a measure of total length of all one
pixel thick open branches) of NF312 staining was measured on the in-
jured hemisphere of the brain sections using ImagePro 6.2 software
(ImagePro, Bethesda MD). The sum of the IOD or sum axon length
from ﬁve saline, six 8 h and four 12 hour methamphetamine treated
rats were measured. Treatment group averages of sum IOD or axon
length and standard errors of themeanwere calculated. Positive staining
levels were identiﬁed by setting threshold levels from control slides
reacted with secondary but no primary antibody. For the NeuroTrace
stained slides images were captured at 20× (1.5zoom) in the CA1 region
of hippocampus. Two sections per rat were imaged and dead cells were
counted manually using ImagePro software. Live cells were round and
contained NeuroTrace labeled (green) cytoplasm and blue (DAPI
labeled) nuclei. Dead cells were very bright cells with condensed cyto-
plasm and nuclei and altered morphology. Average dead cells per rat
and an average number of dead cells per treatment group were calculat-
ed. Four saline and four 8-hour methamphetamine and ﬁve 12 hour
methamphetamine rats were counted and group averages and standard
errors of the mean calculated.
RNA isolation/gene array protocol
Three biological replicates were used for each experimental group
and each replicate was run in triplicate. Total RNA was isolated from
the rat ipsilateral cortex utilizing Trizol LS (Invitrogen) according to
the manufacturer's protocol. To remove any contaminating chemicals
AB
Fig. 1.Behavioral assessments following8 hour delay ofmethamphetamine administration.
Time course values are shown for (A) Neurological Severity Scores (NSS) and (B) foot fault
assessments over 40 days for rats treatedwith saline (red line), 0.125 mg/kg/h (black line),
0.25 mg/kg/h (blue line) or 0.500 mg/kg/h (green line). The dashed line indicates typical
NSS and foot fault scores for uninjured rats. n = a minimum of 8 animals per group.
** = p b 0.01, *** = p b 0.001 relative to saline treated controls.
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Qiagen RNeasy MinElute Cleanup Kit according to the manufacturer's
protocol. RNA was quantiﬁed using a Nano Drop spectrophotometer.
RNA was considered acceptable if the 260/280 and 260/230 ratios were
2.0 or greater. A 1 μg aliquot of total RNA was reverse transcribed to
cDNA using Qiagen's RT2 First Strand Kit. One half of the cDNA reaction
was mixed with 675 μl of Qiagen's 2X RT SYBR Green Mastermix and
624 μl H2O. Thiswas then added to a customarray panel (SABiosciences)
and cycled according to themanufacturer's suggested qPCR protocol on a
Bio-Rad iQ5 thermocycler. Values were normalized for GAPDH. For data
analysis, the ΔΔCt method was used with the aid of the manufacturer's
online software suite RT2 Proﬁler PCR Array Data Analysis version 3.5.
Fold-changes were calculated and results compared to normal controls.
Please note: (2^(- Delta Delta Ct)) is the normalized gene expression
(2^(- Delta Ct)) in the test sample divided the normalized gene expres-
sion (2^(- Delta Ct)) in the Control Sample. Fold-regulation represents
fold-change results in a biologically meaningful way. Fold-change values
greater than one indicate a positive- or an up-regulation, and the fold-
regulation is equal to the fold-change. Controls for this experiment
underwent the trephination surgery but did not receive a TBI.
Measurement of methamphetamine from plasma
Jugular catheterized adult male Wistar rats were purchased from
Charles River Laboratories. Rats were implanted with an Alzet pump
(Alzet Corp., 2001D, 8.4 μl per hour) and a femoral vein catheter as pre-
viously described (Rau et al., 2012). Pump deliverywas calculated based
on pump rate and volume contained within the catheter. Based on the
catheter inner diameter (ID) of 0.635 and a pump rate of 8.4 μl per
hour +/−0.2 μl a catheter length of 2.25 cm delivered methamphet-
amine to the femoral vein at 1 h post-implantation. A total of six blood
draws (500 μl each)were performed on each animal. Animalswere anes-
thetized using 1–3% isoﬂurane andmaintained at a plane of light sedation
throughout the blood draw. Collected blood tubeswere placed on ice and
centrifuged immediately. Samples were spun at 1300 ×g for 10 min.
Supernatants were immediately pulled off and placed in Eppendorf
tubes. Samples were immediately frozen at −80 °C until processing
and testing. Plasma samples were processed using the State of Montana
crime lab extraction protocol and analyzed using LC-MS at the Missoula,
Montana laboratory (Cravey, 1982; S. B., 1996).
Statistical analysis
All data was analyzed using Prizm software. To determine Gaussian
(normal) distribution a Kolmogorof–Smirnov test was performed on all
data sets. Appropriate parametric analysis was performed on data sets
containing two groups using an unpaired, one-tailed T-test (CI = 95%).
Analysis on data sets with more than 2 groups was done using one-
way ANOVA with Tukey's post-hoc to determine statistical signiﬁcance
between groups. A p b 0.05 was considered signiﬁcant.
Results
Methamphetamine improves behavioral outcomes when administration is
delayed until 8 h after injury
We previously demonstrated that methamphetamine provides
robust improvement in both behavioral and cognitive function when
administration occurs within 3 h after severe TBI. However, treatment
within 3 h is not clinically achievable in many cases. Therefore, we fur-
ther characterized the neuroprotective potential and pharmacological
proﬁle of methamphetamine by conducting a dose response study
with administration being delayed until 8 h after injury. Rats received
a severe TBI and, 8 h later, were given an i.v. bolus injection of saline
or methamphetamine (0.42, 0.21, or 0.10 mg/kg), followed by i.v.
infusion for 24 h with saline or methamphetamine (0.50, 0.25, or
0.12 mg/kg/h), respectively. NSS and foot fault assessments were con-
ducted on days 1, 7, 14, 21, 30 and 40 post-injury (Rau et al., 2012).Administration of methamphetamine at the 0.500 mg/kg/h or
0.250 mg/kg/h dose produced signiﬁcant improvements in NSS on
days 14, 21, 30 and 40 post injury (Fig. 1A). However, a signiﬁcant
improvement in neurological scoring for animals treated with
0.500 mg/kg/h dose was observed as early as 7 days post-injury,
suggesting that the higher dose may have a slightly greater effect
on early recovery from the injury. Animals receiving the 0.125 mg/kg/h
dose had a signiﬁcant improvement on day 14 post-injury however
this effect did not persist. On days 1, 7, 21, 30 and 40, post-injury NSS
for the 0.125 mg/kg/h treatment group did not differ from saline treated
animals.
Dexterity, ﬁne motor control and forepaw sensation was assessed
using the foot fault test (Rau et al., 2012). Animals were examined on
days 1, 7, 14, 21, 30, and 40 post-injury. Unlike the NSS assessment, all
doses of methamphetamine improved performance in the foot fault
assessment by day 14 post-injury (Fig. 1B). However, as with the
NSS scoring, the 0.500 mg/kg/h dose showed improvement earlier
(at 7 days post-injury) than the other doses did.
Methamphetamine improves cognitive outcomes when administration is
delayed until 8 h after injury
The dose response effect of methamphetamine on cognitive perfor-
mance following severe TBI was assessed using the Morris water maze
(MWM). Dosing rats with 0.500 mg/kg/h or 0.250 mg/kg/h beginning
8 h after injury signiﬁcantly reduced the time required to locate the
34 T.F. Rau et al. / Experimental Neurology 253 (2014) 31–40escape platform (Fig. 2A). A signiﬁcant improvement in learning was
observed on training days 3, 4, and 5 for rats treated with the
0.500 mg/kg/h dose. Rats treated with this dose behaved similar to
uninjured rats by the third training day. However, rats treated with
0.250 mg/kg/h did not show signiﬁcant improvement over saline treat-
ed controls until the ﬁfth training day. In contrast, the 0.125 mg/kg/h
treated rats showed no signiﬁcant improvement over saline controls
on any of the days tested indicating this dose failed to improve learning
following severe TBI.
After completion of the ﬁve-day training period, we used a
probe trial to assess memory function. Using this assessment of0
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Fig. 2. Treatment with methamphetamine improves learning and memory after severe
TBI. (A) Shows latency times over 5 training days for rats treated with saline (red line),
0.125 mg/kg/h (black line), 0.250 mg/kg/h (blue line) or 0.500 mg/kg/h (green line)
beginning 8 h after severe TBI. The dotted black line indicates the latency times for unin-
jured control rats. (B) Shows the percent time rats spent in each quadrant of the maze
searching for the escape platform. The target quadrant (white bars) is where the escape
platform had previously been located. Non-target quadrants were Q2-4. (C) Shows the
percent of time that rats from each treatment group spent within the thigomataxia
zone. n = 8 animals per group. * = p b 0.05, ** = p b 0.01 relative to saline treated
controls.spatial memory, we found that injured rats treated with either
0.500 mg/kg/h or 0.250 mg/kg/h methamphetamine spent signiﬁ-
cantly greater time in the target quadrant searching for the escape
platform (Fig. 2B) and signiﬁcantly less time (~25%) in the thigmotaxia
zone (Fig. 2C) compared to saline treated, injured animals. The
thigmotaxia zone is the circular area around the outer rim of the tank
and was not included in the four search quadrants. Animals that spend
time in this zone are not actively searching or using visual cues and
thus swim time spent in the thigmotaxia zone represents a random
searchpattern that does not involve active spatialmemory recall. Animals
treatedwith 0.125 mg/kg/hmethamphetamine did not differ from saline
treated, injured animals in the amount of time they spent in the target
quadrant or the thigmotaxia zone, indicating that the 0.125 mg/kg/h
dose of methamphetamine had no effect on memory improvement
after TBI.
Methamphetamine is neuroprotective when administration is delayed up
to 12 h post TBI
To further characterize the pharmacology of methamphetamine as a
potential neuroprotective agent and deﬁne possible parameters of clini-
cal application, we examined the therapeutic window of treatment. To
accomplish this, we delayed delivery of methamphetamine until 12 h
after severe TBI. We again used NSS and foot fault tests to assessA
B
Fig. 3. Methamphetamine administered 12 h after TBI reduced neurological severity
scores. Time course values are shown for (A) Neurological Severity Scores and (B) foot
fault assessments over 40 days for rats treated with saline (red line), or 0.500 mg/kg/h
(blue line). The dashed line indicates typical NSS and foot fault scores for uninjured rats.
n = a minimum of 8 animals per group. * = p b 0.05, ** = p b 0.01, relative to saline
treated controls.
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Fig. 4.Treatmentwith lowdosemethamphetamine improved learning andmemorywhen
delivered 12 h after a severe TBI. (A) Shows latency times over 5 training days for rats
treated with saline (red line), or 0.500 mg/kg/h (blue line) beginning 12 h after severe
TBI. The dotted black line indicates the latency times for uninjured control rats. (B) Shows
the percent time rats spent in each quadrant of themaze searching for the escape platform.
The target quadrant (white bars) iswhere the escape platformhad previously been located.
Non-target quadrants were Q2-4. (C) Shows the percent of time rats from each treatment
group spent within the thigomataxia zone. n = 8 animals per group. * = p b 0.05,
** = p b 0.01, *** = p b 0.001 relative to saline treated controls.
35T.F. Rau et al. / Experimental Neurology 253 (2014) 31–40functional behavior.We observed a signiﬁcant improvement in bothNSS
and foot fault measurements within 7 days following delayed adminis-
tration (Fig. 3).
Spatial learning and reference memory were again assessed in the
MWM (Rau et al., 2012). As with the NSS and foot fault testing, delaying
administration of methamphetamine until 12 h after severe TBI resulted
in signiﬁcantly improved performance in the MWM. Similar to the
8-hour delivery study, we observed a robust improvement in memory
and a signiﬁcant reduction in the time spent in the thigmotaxia zone
(Fig. 4). However, rats treated with methamphetamine beginning at
12 h after injury did not show a signiﬁcant improvement in latency
times until the ﬁfth day of training. This represents a substantial shift
in the learning curve relative to the 8-hour study and indicates that
delaying methamphetamine treatment to 12 h post-TBI reduces im-
provement in this outcome.
Methamphetamine treatment reduces neuronal loss and preserves axon
density after severe TBI
Immunoﬂuorescent analysis was conducted on parafﬁn embedded
brain sections from the injury area. Sections were prepared at 46 days
after injury. As previously described by Ooigawa et al. (2006)we utilized
a ﬂuorescent Nissil stain (NeuroTRACE), to label both live and dead
neurons in injured animals treated with saline or methamphetamine
(Ooigawa et al., 2006). We found that treating rats with 0.500 mg/kg/h
methamphetamine beginning at 8 or 12 h after severe TBI signiﬁcantly
reduced neuronal loss in the CA1 region of the hippocampus compared
to injured, saline treated control animals (Fig. 5). Diffuse axonal injury
is often observed following TBI. Therefore, we assessed the potential of
methamphetamine to preserve axonal density. Using a pan-antibody
for neuroﬁlament, we found that delivering methamphetamine at the
0.500 mg/kg/h dose, beginning 8 h after injury, signiﬁcantly preserved
neuroﬁlament staining within the CA3 region of the hippocampus
when compared to saline treated control animals (Fig. 6). However,
there was no signiﬁcant difference in neuroﬁlament staining in the hip-
pocampus when treatment was delayed until 12 h post-injury.
Pharmacokinetics at a therapeutic dose of methamphetamine
To more fully characterize the pharmacology of methamphetamine
we examined the pharmacokinetic proﬁle of the highest therapeutically
effective dose tested. A 24-hour infusion of methamphetamine at
0.500 mg/kg/h for 24 h generated a Cmax of 25.9 ng/ml and an exposure
of 17 ng/ml/h over a 32-hour period. This produced a total drug expo-
sure of 544 ng/ml. The FDA recommended oral dose for treating ADHD
is up to 25 mg daily (Administration F.a.D, 2007). Based on this dosing
regimen, we calculated a 24-hour total drug exposure of 998 ng/ml,
for a 70 kg human receiving a daily oral dose of 25 mg.We also analyzed
the bioactive metabolite D-amphetamine, and found that exposure to
0.500 mg/kg/h methamphetamine generated a Cmax of 13.3 ng/ml and
a total drug exposure over 32 h of 252 ng/ml (Fig. 7).
Methamphetamine signiﬁcantly alters the expression of genes involved in
multiple pathophysiological pathways
We previously reported that methamphetamine mediates neuropro-
tection through dopamine-dependent activation of a PI3K-AKT signaling
pathway (Rau et al., 2011).We have further demonstrated thatmetham-
phetamine signiﬁcantly reduced apoptosis after severe stroke and TBI
(Rau et al., 2011). In addition to the histological evidence of neuroprotec-
tion presented in this study, we wanted to further deﬁne the potential
mechanisms of methamphetamine-mediated neuroprotection. There-
fore, we conducted a gene array analysis to screen for candidate genes in-
volved in the pathological processes induced by severe TBI. As Table 1
indicates, methamphetamine treatment prevented the increased expres-
sion of several key genes involved in inﬂammatory signaling.Many of thelargest increases (when compared to sham, un-injured animals) we ob-
served in gene expression involved pro-inﬂammatory molecules. For
example, the chemokine CCL2 (11 fold increase, p = 0.0004), the
Toll-like receptor signaling protein Myd88 (3 fold increase,
p b 0.0001) and the pro-inﬂammatory cytokine IL1β (4.6 fold increase,
p = 0.005) were all signiﬁcantly elevated in saline treated TBI injured
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Fig. 5. Methamphetamine is neuroprotective in the CA1 region of the hippocampus at
46 days after severe TBI. Representative micrographs of the CA1 region at Bregma−3.3
show increased numbers of dead cells in saline treated TBI animals (A) compared with
rats treated with 0.500 mg/kg/h methamphetamine at 8 h post TBI (B) or at 12 h post-
TBI (C). Nuclei are stained blue with DAPI. Dead and dying neurons stain brightly green
with NeuroTrace with little or no nuclei (arrows in a). Normal neurons have blue nuclei
and rounded cell morphology with a large cytoplasm that stains less intensely
green (arrowheads in b and c). (D) Shows graphically the average values for each
treatment group. n = 4 animals per group. ** = p b 0.01.
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Fig. 6.Methamphetamine preserves axonal structure. Representative images of the CA3
region show decreased neuroﬁlament staining in saline treated TBI injured animals
(A) compared to TBI rats treated with methamphetamine at 8 h after injury (B). Animals
treated with methamphetamine beginning 12 h post TBI did not show a signiﬁcant
difference from saline treated TBI animals (C). Quantiﬁcation of neuroﬁlament staining
showed signiﬁcantly greater axonal staining (d) in rats treated with methamphetamine
beginning 8 h after injury, but not at 12 h, (D). n = minimum of 4 rats per group.
* = p b 0.05, ** = p b 0.01.
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pression of CCL2, Myd88 or IL1β in the methamphetamine treated
rats. However, methamphetamine treatment did induce a signiﬁcant
increase in the anti-inﬂammatory chemokine CXCL12 (2.2 fold,
p = 0.0001) while saline controls showed no signiﬁcant change. Final-
ly, we observed at least a two-fold increase in the expression of cortico-
tropin releasing hormone (p = 0.0006), and neurotensin (p = 0.008)
in methamphetamine treated rats compared to a 1.7 fold decrease
(p = 0.002) in corticotropin releasing hormone and no signiﬁcant
change in neurotensin in saline treated controls.
Discussion
In this study we have established 0.250 mg/kg/h as the lowest effec-
tive dose of methamphetamine that signiﬁcantly reduces neurological
dysfunction and cognitive impairment when delivered 8 h after a severe
AB
Fig. 7. Pharmacokinetics of D-methamphetamine and its metabolite, D-amphetamine. The
concentrations of methamphetamine (A) and amphetamine (B) detected in the plasma of
rats treated with methamphetamine at a dose of 0.500 mg/kg/h for 24 h are shown.
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behavioral and cognitive improvementswhen a dose of 0.500 mg/kg/h is
delivered up to 12 h after a severe TBI. Immediately after TBI, transient
mitochondrial swelling occurs, which after 12 h, leads to irreversible dif-
fuse axonal injury (Blaylock and Maroon, 2011; Saulle and Greenwald,
2012; Stoica and Faden, 2010; Thompson et al., 2005). Thus, the inability
of methamphetamine to preserve axons after a 12-hour delay may di-
rectly correlate with these axonal studies. It may also explain why
delaying methamphetamine treatment until 12 h after injury had less
of an impact on the learning assessments. Despite the loss of neuroﬁla-
ment staining in the CA3 region, animals in the 12-hour delay group still
demonstrated a signiﬁcant improvement in memory. The disparity be-
tween the learning andmemory outcomesmay be explained by our ob-
servation that the 12-hour delay group still had a signiﬁcant
preservation of CA1 pyramidal neurons, which are critical in memory
consolidation (Wittenberg et al., 2002). This suggests that low doseTable 1
Gene expression analysis in TBI rats.
Fold change
Gene Saline/normal Methamphetamine/normal
CCL2 11 (0.0004) NSC
MyD88 3 (0.0001) NSC
IL1b 4.6 (0.005) NSC
CXCL12 NSC 2.2 (0.0001)
CRH −1.7 (0.002) 2 (0.0006)
neurotensin NSC 2 (0.008)
NSC = no signiﬁcant change. P values relative to normal (uninjured) rats are shown in
parenthesis.methamphetamine can bedelivered up to 12 h after injury and still pro-
tect highly vulnerable neurons within the hippocampus.
Of particular interest in this studywas ourﬁnding thatmethamphet-
amine improved NSS scoring and foot faults but reduced cell death and
axonal loss only in the hippocampus. A comprehensive literature search
provides a spectrum of contradicting outcomes in the context of motor
function relative to cortical injury in the rat LFP model. Selected LFP
studies have shown a correlation between a reduction in cortical lesion
volume and motor function improvement (Luo et al., 2013; Otani et al.,
2007). In contrast, other studies have shown improved motor behavior
with no decrease in cortical lesion volume (Lippert-Gruener et al., 2007).
Further studies have reported neuroprotective treatments that im-
proved lesion volume but did not improve motor function (Marklund
et al., 2001).
Others have shown a correlation between reduced hippocampal
damage following LFP-induced TBI and improved motor function
(Lee et al., 2004). Similar to our studies, Lee et al. (2004) only reported
pathological alterations in the hippocampus. Supporting this observation,
Gheysen et al. (2010) presented evidence that the hippocampus contrib-
utes to early and late stagemotor sequence learning that is critical to per-
formance of motor function tasks (Gheysen et al., 2010). Further
supporting the role of the hippocampus in motor tasks Grossberg and
Merrill (1996), found that the hippocampus plays a key role in control-
ling adaptive timing and spatial orientation which are two key elements
of balance and coordination, both of which are tested in the NSS scoring
and foot fault analysis (Grossberg andMerrill, 1996; Gorchetchnikov and
Grossberg, 2007). Speciﬁcally, Grossberg found clear evidence that
the hippocampal circuits play a key role in cerebellar timing control,
spatial orientation, and motor outputs (Grossberg and Merrill, 1996;
Gorchetchnikov and Grossberg, 2007; Grossberg and Seidman, 2006).
The LFP model creates a global stress on the brain and generates the
coup-contre coup effect found in closed head injuries (Xiong et al.,
2012). Interestingly, closed head injuries can produce motor deﬁcits
but fail to generate a cortical lesion, (or measurable damage) within
the motor cortex (Heitger et al., 2006). Heitger et al. (2006) also found
that despite the lack of measureable tissue abnormalities, a mild closed
head TBI could produce motor deﬁcits up to 1 year following the injury
(Heitger et al., 2006).
Another potential explanation may be linked to white matter track
remodeling that occurs after TBI. We previously reported (Ding et al.,
2013) that methamphetamine treatment improved foot faults and
NSS scores but did not decrease cortical lesion volumes (Ding et al.,
2013). However, we did observe a statistically signiﬁcant increase in
white matter track remodeling within the peri-lesional region of the
cortex in methamphetamine treated animals that was not present in
saline treated controls. Interestingly, this signiﬁcant changewas not ob-
served until 5 and 6 weeks post injury suggesting methamphetamine
treatment may have a long-term effect irrespective of the initial lesion
core (Ding et al., 2013).
After administration, methamphetamine rapidly concentrates in the
brain at signiﬁcantly higher levels than in the plasma (up to 13 times
greater) and induces the immediate release of dopamine, norepinephrine
and serotonin (Administration F.a.D, 2007; Krasnova and Cadet, 2009; S.
B., 1996). Methamphetamine also blocks the degradation of these neu-
rotransmitters, resulting in prolonged neuronal signaling (Cadet and
Krasnova, 2009; Krasnova and Cadet, 2009). When used at very high
doses it produces profound euphoria, increased heart rate, respiration,
agitation and dopamine mediated neurotoxicity (Cadet and Krasnova,
2009; Krasnova and Cadet, 2009). However, when administered at low
doses, methamphetamine produces a more controlled release of cate-
cholamines, capable of activating multiple neuroprotective pathways
in the brain (Feeney and Hovda, 1983; Feeney et al., 1981, 1982; Rau
et al., 2011, 2012). Currently, methamphetamine is FDA approved for
the treatment of ADHD and obesity as an oral daily dose of up to
25 mg (Administration F.a.D, 2007). Under this dosing regimen, the
total 24-hour exposure for a 70 kg adult would be twice what we
38 T.F. Rau et al. / Experimental Neurology 253 (2014) 31–40observed with the highest therapeutic dose (0.500 mg/kg/h) tested in
rats. However, recently published data indicates that a single i.v. injec-
tion of 0.5 mg/kg methamphetamine in a healthy human test subjects
produced a 24 h total exposure similar to what a daily oral dose of
25 mg would produce (Mendelson et al., 2006). This suggests that the
current FDA approved dose may more than sufﬁcient to provide neuro-
protective efﬁcacy in humans.
A recent study by Vaarmann et al. (2013) suggested that dopamine
prevents delayed calcium deregulation and glutamate excitotoxicity
(Vaarmann et al., 2013). This is relevant as TBI produces glutamate-
mediated excitotoxicity and calcium dysregulation. This effect was
demonstrated to be dependent on the activation of D1 and D2 receptors
and was enhanced by the addition of a monoamine oxidase inhibitor.
We have previously reported that methamphetamine-mediated neuro-
protection in a stroke model was dependent on dopamine activation of
D1 and D2 receptors (Administration F.a.D, 2007). As a secondary effect,
methamphetamine also inhibits monoamine oxidase activity. Thus,
methamphetamine may be exerting a neuroprotective effect by
preventing delayed calcium deregulation and excitotoxicity. Further-
more, we have also previously demonstrated that delivering low dose
methamphetamine increased protein kinase B (AKT) phosphorylation
in a dopamine dependent manner (Rau et al., 2011). This ﬁnding is
also linked to neuroprotection as AKT is a central kinase that blocks
multiple pathways of apoptotic death including BAD, Bim, GSK3β, p53
and Fox01 (Rau et al., 2011; Zhang et al., 2005). Further supporting
the potential anti-apoptosis effect of AKT phosphorylation, we found
thatmethamphetamine treatment signiﬁcantly reduced apoptotic neu-
ronal death in the hippocampus.
In addition to apoptosis, TBI induces a cascade of pathophysiology
involving a broad spectrum of gene expression changes. We observed
large changes in the expression of key genes that inﬂuence cerebral
inﬂammation 32 h after TBI. Speciﬁcally, methamphetamine treatment
signiﬁcantly reduced cortical expression of three key mediators of in-
ﬂammation: CCL2, MyD88 and IL1ß.
The pro-inﬂammatory chemokine CCL2 (MCP-1) increased 11
fold in injured, saline treated animals, whereas treatment with
methamphetamine completely blocked this increase. A member of
the monocyte chemotactic protein (MCP) family, CCL2 is expressed
by astrocytes, macrophages, and reactive microglia, and is one of
the most potent chemo-attractants that recruit monocytes to damaged
areas (Sozzani et al., 1994a, 1994b). In addition, there is direct evidence
that CCL2 contributes to the pathogenesis and development of brain
lesions from ischemia and excitotoxic insults, both of which play a role
in the development of pathology following TBI (Semple et al., 2010,
2011). Supporting this ﬁnding is the observation that CCL2 knockout
mice have signiﬁcantly lower neurological impairment following TBI rel-
ative towild typemice (Lloyd et al., 2008). A rapid increase in CCL2 is ob-
served within human spinal ﬂuid following severe TBI and CCL2 levels
remain signiﬁcantly elevated over controls for up to 10 days post-
injury (Semple et al., 2010). Semple et al. (2010) recently reported that
increased levels of CCL2 were detected in the serum of patients who
died shortly after TBI (Semple et al., 2010). Thus, a direct correlation ex-
ists between increased CCL2 levels, and increased neuro-inﬂammation
and neuropathology following TBI. Our ﬁndings suggest that metham-
phetamine mediates neuroprotection in part, through the reduction of
this critical neuro-inﬂammatory mediator.
The concept that methamphetamine treatment reduces post-
traumatic inﬂammation is further supported by the fact that TBI
induced a 3-fold increase in the expression of the myeloid differentia-
tion primary response protein 88 (Myd88) gene, while a signiﬁcant in-
crease in Myd88 expression was absent in the methamphetamine
treated rats. Myd88 is a key adaptor protein involved in Toll-like recep-
tor and pro-inﬂammatory cytokine signal transduction. Activation of
Toll-like receptors results in the recruitment of Myd88 and subsequent
activation of the transcription activator, nuclear factor kappaB (NF-κB).
NF-κB induces the rapid expression of pro-inﬂammatory moleculesincluding tumor necrosis factor a (TNF-α), IL-1β, interleukin-6 (IL-6),
and intracellular adhesion molecule-1 (ICAM-1) (G.Z. Li et al, 2011.;
W. Li et al., 2013; Ling et al., 2013). Thismay explain the 4.6 fold increase
we observed in IL-1β after TBI. Li et al. (2011) demonstrated a signiﬁ-
cant increase in Myd88 positive cells surrounding the TBI injury zone
and a positive correlation between the expression of Myd88, NF-κB,
and IL-1β (G.Z. Li et al., 2011; W. Li et al., 2013; Zhang et al., 2012).
Further supporting the inﬂammatory role of Myd88 in TBI, Li et al.
(2011) found that Myd88 was signiﬁcantly elevated 72 h after TBI in
humans andwas actively expressed in neurons, astrocytes, andmicrog-
lia (G.Z. Li et al., 2011; W. Li et al., 2013). This correlated with a signiﬁ-
cant increase in TNF-α and IL-1β (W. Li et al., 2013; G.Z. Li et al., 2011).
In our experiments, we observed Myd88, CCL-2, and IL-1β expres-
sion levels in methamphetamine treated TBI animals that were not sig-
niﬁcantly different from uninjured sham controls 32 h after TBI. The
exact mechanism(s) of how methamphetamine produced the gene
changes we observed are not known, and there are no current studies
that link methamphetamine to decreased neuroinﬂammation. There
are studies, however, that suggest a link between dopamine signaling
and decreased inﬂammation. Shao et al. (2012) demonstrated that
the astrocytic D2 dopamine receptor (D2R) potently suppressed
neuroinﬂammation in the rodent brain by inﬂuencing expression of
αB-crystallin (CRYAB) (Shao et al., 2012). Coffeen et al. (2010) demon-
strated that brain inﬂammation resulted in a signiﬁcant decrease in the
release of dopamine, DOPAC, andHVA. Inﬂammation also decreased the
mRNA levels of the D1R suggesting that inﬂammation negatively regu-
lates dopamine signaling (Coffeen et al., 2010). In our previous studies
of methamphetamine using a focal embolic stroke model we found
that low dose methamphetamine exerted a neuroprotective effect
that was dependent on a PI3K/AKT pathway. Interestingly, activation
of the PI3K/AKT pathway, in addition to suppressing apoptotic factors,
is necessary for activation of nuclear factor erythroid 2-related factor 2
antioxidant response element (Nrf2-ARE). Nrf2-ARE is commonly in-
volved in the transcriptional regulation of genes encoding antioxidant
proteins such as glutathione (GSH) under stress conditions (Chen
et al., 2009; Jin et al., 2008). Thus, increasing the presence and activity
of Nrf2-ARE through AKT would likely decrease ROS production after
TBI, and there is a growing body of evidence indicating that ROS directly
affects the expression of pro-inﬂammatory genes. Gupta et al. (2012)
demonstrated that ROS activate various transcription factors such as
nuclear factor kappa-light-chain-enhancer of activated B cells [NF-κB],
activator protein-1, hypoxia-inducible factor-1α, and signal transducer
and activator of transcription 3, resulting in the expression of proteins
that control inﬂammation, (Gupta et al., 2012). While we do not know
if a methamphetamine-dopamine-PI3K/AKT pathway is activating
Nrf2-ARE leading to decreased ROS, the potential neuroprotective path-
way warrants future investigation. An Nrf2-ARE mediated decrease in
ROS may be altering expression of the pro-inﬂammatory genes we ob-
served in the cortex of methamphetamine treated TBI animals. Testing
these hypotheses in future studies will hopefully elucidate the mecha-
nism(s) by which methamphetamine reduces cognitive and neurologi-
cal impairment after TBI.
We also observed additional changes in the gene expression proﬁle
that further suggest methamphetamine treatment impacts multiple
pathophysiological pathways. For example, we detected a 2-fold in-
crease in the expression of corticotropin-releasing hormone (CRH) in
the brains of methamphetamine treated rats following TBI, compared
to a 1.7 fold decrease in saline treated controls. CRH has been shown
to protect primary cortical and hippocampal neurons from apoptosis
when administered 8 h after an acute neurological insult (Stevens
et al., 2003). The in-vivo administration of CRH after global ischemia
in Wistar rats increased survival of CA1 neurons by 61% (Charron
et al., 2008). Similar to our observations here, Charron et al. (2008)
demonstrated that CRH treatment could be delayed until 8 h after
ischemic injury and that treatment signiﬁcantly improved spatialmem-
ory and preserved CA1 neuronal survival (Charron et al., 2008). Finally,
39T.F. Rau et al. / Experimental Neurology 253 (2014) 31–40Koutmani et al. (2013) recently demonstrated that CRH promotes the
proliferation and survival of neuronal progenitor cells (Koutmani
et al., 2013). This is noteworthy aswe recently demonstrated thatmeth-
amphetamine treated rats have signiﬁcantly more doublecortin posi-
tive, immature neurons within the subgranular zone of the dentate
gyrus after TBI compared to saline treated controls (Administration
F.a.D, 2007). This suggests thatmethamphetaminemay promote prolif-
eration and survival of neuronal precursors through the activity of CRH.Conclusion
The data presented in this study indicate that low dose metham-
phetamine is neuroprotective when delivered 8–12 h after a severe
TBI in a rodentmodel. In addition to reducing neurological and cognitive
impairment, methamphetamine reduced neuronal death in the hippo-
campus when delivered up to 12 h after TBI. These data, combined
with our previously published studies, suggest a novel, neuroprotective
use for methamphetamine.References
Administration F.a.D, 2007. Desoxyn Product Information.
Beauchamp, K., et al., 2008. Pharmacology of traumatic brain injury: where is the “golden
bullet”? Mol. Med. 14 (11–12), 731–740.
Blaylock, R.L., Maroon, J., 2011. Immunoexcitotoxicity as a central mechanism in chronic
traumatic encephalopathy-A unifying hypothesis. Surg. Neurol. Int. 2 (11–12), 107.
Block, M.L., Zecca, L., Hong, J.S., 2007. Microglia-mediated neurotoxicity: uncovering the
molecular mechanisms. Nat. Rev. Neurosci. 8 (1), 57–69.
Brown, G.C., Neher, J.J., 2010. Inﬂammatory neurodegeneration and mechanisms of
microglial killing of neurons. Mol. Neurobiol. 41 (2-3), 242–247.
Cadet, J.L., Krasnova, I.N., 2009. Molecular bases of methamphetamine-induced neurodegen-
eration. Int. Rev. Neurobiol. 88, 101–119.
Charron, C., et al., 2008. In vivo administration of corticotropin-releasing hormone at re-
mote intervals following ischemia enhances CA1 neuronal survival and recovery of
spatial memory impairments: a role for opioid receptors. Behav. Brain Res. 188 (1),
125–135.
Chen, W., S.Z, Wang, X.J., Jiang, T., Huang, Z., Fang, D., Zhang, D.D., 2009. Direct interaction
between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant
response. Mol. Cell 34 (6), 663–673.
Coffeen, U., et al., 2010. Inﬂammatory nociception diminishes dopamine release and in-
creases dopamine D2 receptor mRNA in the rat's insular cortex. Mol. Pain 6, 75.
Cravey, B., 1982. Introduction to Forensic Toxicology; Rationale of Analytical Method Sec-
tion 90–91.
Daneshvar, D.H., et al., 2011. Long-term consequences: effects on normal development
proﬁle after concussion. Phys. Med. Rehabil. Clin. N. Am. 22 (4), 683–700 (ix).
Dempsey, K.E., et al., 2009. Landstuhl Regional Medical Center: traumatic brain injury
screening program. J Trauma Nurs 16 (1), 6–7 (10–12).
Ding, G.L., et al., 2013.MRIof neuronal recovery after low-dosemethamphetamine treatment
of traumatic brain injury in rats. PLoS One 8 (4), e61241.
Dolan, S., et al., 2012. Neuropsychological sequelae of PTSD and TBI following war deploy-
ment among OEF/OIF veterans. Neuropsychol. Rev. 22 (1), 21–34.
Elder, G.A., et al., 2010. Blast-induced mild traumatic brain injury. Psychiatr. Clin. North
Am. 33 (4), 757–781.
Feeney, D.M., Hovda, D.A., 1983. Amphetamine and apomorphine restore tactile
placing after motor cortex injury in the cat. Psychopharmacology (Berl.) 79
(1), 67–71.
Feeney, D.M., Gonzales, A., Law, W.A., 1981. Amphetamine restores locomotor function
after motor cortex injury in the rat. Proc. West. Pharmacol. Soc. 24, 15–17.
Feeney, D.M., Gonzalez, A., Law, W.A., 1982. Amphetamine, haloperidol, and experience
interact to affect rate of recovery after motor cortex injury. Science 217 (4562),
855–857.
Gheysen, F., et al., 2010. Hippocampal contribution to early and later stages of implicit
motor sequence learning. Exp. Brain Res. 202 (4), 795–807.
Gorchetchnikov, A., Grossberg, S., 2007. Space, time and learning in the hippocampus:
howﬁne spatial and temporal scales are expanded into population codes for behavioral
control. Neural Netw. 20 (2), 182–193.
Grossberg, S., Merrill, J.W., 1996. The hippocampus and cerebellum in adaptively timed
learning, recognition, and movement. J. Cogn. Neurosci. 8 (3), 257–277.
Grossberg, S., Seidman, D., 2006. Neural dynamics of autistic behaviors: cognitive, emo-
tional, and timing substrates. Psychol. Rev. 113 (3), 483–525.
Gupta, S.C., et al., 2012. Upsides and downsides of reactive oxygen species for cancer: the
roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid.
Redox Signal. 16 (11), 1295–1322.
Heitger, M.H., et al., 2006. Motor deﬁcits and recovery during the ﬁrst year following mild
closed head injury. Brain Inj. 20 (8), 807–824.
Jin, W., et al., 2008. Disruption of Nrf2 enhances upregulation of nuclear factor-kappaB
activity, proinﬂammatory cytokines, and intercellular adhesion molecule-1 in the
brain after traumatic brain injury. Mediat. Inﬂamm. 2008, 725174.Koutmani, Y., et al., 2013. Corticotropin-releasing hormone exerts direct effects on
neuronal progenitor cells: implications for neuroprotection. Mol. Psychiatry 18
(3), 300–307.
Krasnova, I.N., Cadet, J.L., 2009. Methamphetamine toxicity and messengers of death.
Brain Res. Rev. 60 (2), 379–407.
Lee, L.L., et al., 2004. Neuroprotection in the rat lateral ﬂuid percussionmodel of traumatic
brain injury by SNX-185, an N-type voltage-gated calcium channel blocker. Exp.
Neurol. 190 (1), 70–78.
Li, G.Z., et al., 2011. Expression of myeloid differentiation primary response protein 88
(Myd88) in the cerebral cortex after experimental traumatic brain injury in rats.
Brain Res. 1396, 96–104.
Li, W., et al., 2013. Enhanced cortical expression of myeloid differentiation primary response
protein 88 (Myd88) in patients with traumatic brain injury. J. Surg. Res. 180 (1),
133–139.
Ling, H.P., et al., 2013. Expression of intestinal myeloid differentiation primary response
protein 88 (Myd88) following experimental traumatic brain injury in a mouse
model. J. Surg. Res. 179 (1), e227–e234.
Lippert-Gruener, M., et al., 2007. Late effects of enriched environment (EE) plus multi-
modal early onset stimulation (MEOS) after traumatic brain injury in rats: Ongoing
improvement of neuromotor function despite sustained volume of the CNS lesion.
Exp. Neurol. 203 (1), 82–94.
Lloyd, E., et al., 2008. Suppression of acute proinﬂammatory cytokine and chemokine upreg-
ulation by post-injury administration of a novel small molecule improves long-term
neurologic outcome in a mouse model of traumatic brain injury. J. Neuroinﬂammation
5, 28.
Luo, T., et al., 2013. Propofol limits microglial activation after experimental brain trauma
through inhibition of nicotinamide adenine dinucleotide phosphate oxidase. Anes-
thesiology 119 (6), 1370–1388.
Marklund, N., et al., 2001. Free radical scavenger posttreatment improves functional and
morphological outcome after ﬂuid percussion injury in the rat. J. Neurotrauma 18 (8),
821–832.
Martin, E.M., et al., 2008. Traumatic brain injuries sustained in the Afghanistan and Iraq
wars. J. Trauma Nurs. 15 (3), 94–99 (quiz 100–1).
Mendelson, J., et al., 2006. Human pharmacology of themethamphetamine stereoisomers.
Clin. Pharmacol. Ther. 80 (4), 403–420.
Okie, S., 2005. Traumatic brain injury in the war zone. N. Engl. J. Med. 352 (20),
2043–2047.
Ooigawa, H., et al., 2006. The fate of Nissl-stained dark neurons following traumatic brain
injury in rats: difference between neocortex and hippocampus regarding survival
rate. Acta Neuropathol. 112 (4), 471–481.
Otani, N., et al., 2007. Role of the activated extracellular signal-regulated kinase pathway
on histological and behavioral outcome after traumatic brain injury in rats. J. Clin.
Neurosci. 14 (1), 42–48.
Pitkanen, A., et al., 2009. From traumatic brain injury to posttraumatic epilepsy: what
animal models tell us about the process and treatment options. Epilepsia 50 (Suppl. 2),
21–29.
Prevention C.f.D.C.a, 2006. Traumatic Brain Injury in the United States: Emergency
Department Visits, Hospitalizations and Deaths 2002–2006.
Rau, T.F., et al., 2011. Low dose methamphetamine mediates neuroprotection through a
PI3K-AKT pathway. Neuropharmacology 61 (4), 677–686.
Rau, T.K., BS, Rova, A.R., Brooks, D.M., Poulsen, D.J., 2012. Treatment with low dose meth-
amphetamine improves behavioral and cognitive function after severe traumatic
brain injury. J. Trauma Acute Care Surg. 73 (7) (July).
Reeves, R.R., Panguluri, R.L., 2011. Neuropsychiatric complications of traumatic brain injury.
J. Psychosoc. Nurs. Ment. Health Serv. 49 (3), 42–50.
S. B., 1996. The Merck index: an encyclopedia of chemical, drugs, and biological.
Saulle, M., Greenwald, B.D., 2012. Chronic traumatic encephalopathy: a review. Rehabil.
Res. Pract. 2012, 816069.
Schober, M.E., et al., 2012. Developmental traumatic brain injury decreased brain derived
neurotrophic factor expression late after injury. Metab. Brain Dis. 27 (2), 167–173.
Semple, B.D., et al., 2010. Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence
from severe TBI patients and CCL2−/− mice. J. Cereb. Blood Flow Metab. 30 (4),
769–782.
Semple, B.D., Frugier, T., Morganti-Kossmann, M.C., 2011. CCL2 modulates cytokine pro-
duction in cultured mouse astrocytes. J. Neuroinﬂammation. 7, 67.
Shao, W., et al., 2012. Suppression of neuroinﬂammation by astrocytic dopamine D2
receptors via alphaB-crystallin. Nature 494 (7435), 90–94.
Shultz, S.R., et al., 2012. Repeated mild lateral ﬂuid percussion brain injury in the rat
causes cumulative long-term behavioral impairments, neuroinﬂammation, and
cortical loss in an animal model of repeated concussion. J. Neurotrauma 29 (2),
281–294.
Sozzani, S., et al., 1994a. Receptors and transduction pathways for monocyte chemotactic
protein-2 and monocyte chemotactic protein-3. Similarities and differences with
MCP-1. J. Immunol. 152 (7), 3615–3622.
Sozzani, S., et al., 1994b. Synergism between platelet activating factor and C–C
chemokines for arachidonate release in human monocytes. Biochem. Biophys. Res.
Commun. 199 (2), 761–766.
Stevens, S.L., et al., 2003. Reduced cerebral injury in CRH-R1 deﬁcient mice after focal
ischemia: a potential link to microglia and atrocytes that express CRH-R1. J. Cereb.
Blood Flow Metab. 23 (10), 1151–1159.
Stoica, B.A., Faden, A.I., 2010. Cell death mechanisms and modulation in traumatic brain
injury. Neurotherapeutics 7 (1), 3–12.
Thompson, H.J., et al., 2005. Lateral ﬂuid percussion brain injury: a 15-year review and
evaluation. J. Neurotrauma 22 (1), 42–75.
Vaarmann, A., et al., 2013l. Dopamine protects neurons against glutamate-induced
excitotoxicity. Cell Death Dis. 4, e455.
40 T.F. Rau et al. / Experimental Neurology 253 (2014) 31–40Wittenberg, G.M., Sullivan, M.R., Tsien, J.Z., 2002. Synaptic reentry reinforcement
based network model for long-term memory consolidation. Hippocampus 12
(5), 637–647.
Xiong, Y., Mahmood, A., Chopp, M., 2012. Animal models of traumatic brain injury. Nat.
Rev. Neurosci. 14 (2), 128–142.Zhang, X., et al., 2005. Bench-to-bedside review: apoptosis/programmedcell death triggered
by traumatic brain injury. Crit. Care 9 (1), 66–75.
Zhang, Z., et al., 2012. Immunolocalization of Toll-like receptors 2 and 4 as well as
their endogenous ligand, heat shock protein 70, in rat traumatic brain injury.
Neuroimmunomodulation 19 (1), 10–19.
